Insights & Perspectives

Filter by










Therapeutic Area / Research

Year Starting

Year Ending

Search Insights:
Showing 1 to 10 of 334
Filter by: Unfiltered

Blog Post | Aug 22, 2014

Will reclassification of hydrocodone products place added burden on pain patients and the healthcare system?

Pain is a huge market. I’ve had pain, and you have too. You might be experiencing pain right now. It’s estimated that more than a billion people worldwide are dealing with pain in one form or another. It can range from acute (like a headache) to chronic (like arthritis). It can be difficult to treat because people experience pain so differently. What one person considers mild pain, another might rate as severe.

Read more | Share

Newsletter | Aug 18, 2014

Kantar Health Catalyst, August 2014

Read more | Share

Blog Post | Aug 18, 2014

Social Listening: Gathering insights through the authentic “voice of the patient”

The social media environment currently provides thousands of online outlets for patients across all disease areas to discuss healthcare issues, and patients are talking in ever-growing numbers. This has resulted in the availability of large volumes of online patient-to-patient discussions around issues that are directly relevant to many of the business issues facing the pharmaceutical industry. It is imperative to tap into the content of these discussions to provide true, actionable recommendations around these business issues.

Read more | Share

Blog Post | Jul 31, 2014

Brand marketing is dead. Long live brand marketing!

In pharma, you need a cohesive approach to brand marketing that must embrace three key elements: Rigorous, evidence-based “scientific” planning to properly understand your brand position and opportunities; coordination across the payer-, prescriber- and patient-focused teams; and forward-looking strategy and executable implementation that is constantly looking for improvements.

Read more | Share

White Paper | Jul 25, 2014

Key Findings from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

This issue of Oncology Conference Insight highlights significant information presented at ASCO 2014, which took place May 30-June 3 in Chicago, Illinois. Our goal is to provide our clients with the latest information presented at oncology meetings.

Read more | Share

Infographic | Jul 24, 2014

Awareness and Treatment of Hepatitis C

Hepatitis C is a viral infection that is spread through blood-to-blood contact. Treatment for chronic hepatitis often involves a combination of pegylated interferon and ribavirin. However, people with different genotypes respond differently to treatment, some better than others. According to results from Kantar Health’s National Health and Wellness Survey, treatment of hepatitis C is relatively low. And although a patient’s genotype can affect how well they respond to treatment, awareness of genotype and viral load is low.

Blog Post | Jul 24, 2014

There’s no good in getting a diagnosis of what has already happened

The new reality of brand marketing in the pharma industry is that any diagnostic tool needs to be clearly looking forward toward opportunities in the future – and that’s the main difference between it and all the approaches that have gone before.

Read more | Share

Blog Post | Jul 21, 2014

Uncovering the missed opportunities for maximizing your brand potential

A question: How can you maximize the potential of your brand? Put another way: How do you know what opportunities for maximizing that potential you are missing in the first place? Focusing your resources on the right areas will help you identify and exploit these opportunities – but first you need to know what they are.

Read more | Share

Infographic | Jul 16, 2014

Is pharma brand marketing dead?

The old marketing model of diagnosing market conditions, developing tactics to implement strategies, and monitoring for success no longer applies. Today, it's all about customer experience, market access, and strategy execution.

Blog Post | Jul 16, 2014

Beyond KRAS exon 2: Research at ASCO and Important Treatment Implications for Metastatic Colorectal Cancer

New biomarker data in metastatic colorectal cancer (mCRC) presented at ASCO 2014 showed clinical implications of RAS mutations. The influence of RAS mutations on testing and treatment patterns of mCRC has profound implications on a tumor’s behavior throughout the course of the disease.

Read more | Share
Page  < 123456789 >